𧏠đŹ đ
In a recent study published in eClinicalMedicine, researchers assess the use of fecal microbiota transplantation to enhance the efficacy of anti-programmed cell death protein 1 (PD-1) therapy for patients with microsatellite stable metastatic colorectal cancer.
Study: Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN215). Image Credit: Peakstock / Shutterstock.com.
Background